Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.14B
EPS-6.8600
P/E Ratio-1.58
Earnings Date08/10/2026

bhvn

Operating Expenses

Last Annual Value

741.24M

3-Year CAGR

9%

5-Year CAGR

45%

10-Year CAGR

4%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Operating Expenses

BHVN · NYSE
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
741.24M
19.3%27.6%N/A 
492.74M
-3.2%10.9%26.1%
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
218.10M
20.9%54.0%N/A
315.47M
45.7%55.8%N/A
88.33M
20.6%N/AN/A
221.38M
36.4%N/AN/A
213.54M
6.0%7.1%31.0%
288.90M
88.1%66.5%7.5%
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.81, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $10.81